Stemline Therapeutics (STML) Downgraded by BidaskClub to “Hold”

BidaskClub downgraded shares of Stemline Therapeutics (NASDAQ:STML) from a buy rating to a hold rating in a research note released on Tuesday morning, BidAskClub reports.

Several other research analysts have also recently weighed in on STML. HC Wainwright reissued a buy rating and set a $35.00 price target on shares of Stemline Therapeutics in a research report on Friday, January 25th. Piper Jaffray Companies reissued an overweight rating on shares of Stemline Therapeutics in a research report on Wednesday, February 6th. Zacks Investment Research cut shares of Stemline Therapeutics from a hold rating to a sell rating in a research report on Wednesday, February 27th. ValuEngine raised shares of Stemline Therapeutics from a hold rating to a buy rating in a research report on Thursday, March 21st. Finally, Roth Capital set a $33.00 price target on shares of Stemline Therapeutics and gave the company a buy rating in a research report on Friday, May 10th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $25.20.

Shares of STML stock opened at $14.30 on Tuesday. The stock has a market cap of $701.32 million, a PE ratio of -4.78 and a beta of 1.20. Stemline Therapeutics has a twelve month low of $7.82 and a twelve month high of $20.55.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million for the quarter, compared to analysts’ expectations of $2.61 million. Analysts expect that Stemline Therapeutics will post -2.24 earnings per share for the current year.

In other Stemline Therapeutics news, CEO Ivan Bergstein sold 22,905 shares of the company’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $12.03, for a total value of $275,547.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Kenneth Hoberman sold 10,557 shares of the company’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $12.05, for a total transaction of $127,211.85. The disclosure for this sale can be found here. Insiders sold 180,999 shares of company stock worth $2,048,415 in the last ninety days. 14.80% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stemline Therapeutics in the first quarter valued at about $36,000. Great West Life Assurance Co. Can acquired a new position in Stemline Therapeutics in the fourth quarter valued at about $47,000. Legal & General Group Plc lifted its position in Stemline Therapeutics by 27.1% in the fourth quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,120 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new position in Stemline Therapeutics in the first quarter valued at about $102,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in Stemline Therapeutics by 327.0% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 6,527 shares during the last quarter. 47.73% of the stock is currently owned by institutional investors.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

See Also: Green Investing

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.